Navigation Links
Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results
Date:3/13/2008

436,990

Research and

development 7,288,460 2,678,749 20,554,105 9,214,759

Selling, general and

administrative 3,946,050 2,374,984 11,155,194 6,912,853

Total Operating

Expenses 11,263,739 5,095,132 31,949,728 16,564,602

LOSS FROM OPERATIONS (9,925,830) (4,668,805) (28,150,207) (15,582,856)

Interest income 1,217,439 290,842 4,254,024 830,870

NET LOSS $(8,708,391) $(4,377,963) $(23,896,183) $(14,751,986)

Basic and diluted net

loss per share $(0.11) $(0.07) $(0.32) $(0.24)

Shares used in computing

net loss per share,

basic and diluted 77,459,803 65,402,770 74,317,930 62,610,265

HALOZYME THERAPEUTICS, INC.

CONSOLIDATED BALANCE SHEETS

AS OF DECEMBER 31, 2007 AND 2006

2007 2006

ASSETS:

Cash and cash equivalents $97,679,085 $44,189,403

Accounts receivable 779,825 363,565

Inventory 703,468 442,492

Prepaid expenses and other assets 2,014,680 598,090

Total current assets 101,177,058 45,593,550

Property and equipment, net 2,283,316 497,770

Total Assets $103,460,374 $46,091,320

LIABILITIES AND STOCKHOLDERS' EQUITY:

Accounts payable $3,055,637 $2,017,395

Accrued expenses 2,502,259 1,011,153

Deferred revenue 3,306,225 1,221,992

Total current liabilities 8,864,121 4,250,540
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Baxter and Halozyme Announce Collaboration for Development of Subcutaneous GAMMAGARD LIQUID(TM) Administration Using Enhanze(TM) Technology
2. Halozyme Therapeutics to Present at UBS 2007 Global Life Sciences Conference
3. Halozyme Therapeutics Reports 2007 Third Quarter Financial Results
4. Halozyme Therapeutics Amends Stockholder Rights Plan
5. Halozyme Therapeutics to Present at the BIO CEO and Investor Conference and the Roth Growth Stock Conference
6. Halozyme Therapeutics to Hold Pipeline Update Conference Call on March 14
7. Halozyme Therapeutics Presents Favorable New Safety and Pharmacokinetic Data on rHuPH20 Enzyme Produced Via New Manufacturing Process at European Federation for Pharmaceutical Sciences
8. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
9. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
10. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
11. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... N.C. , Sept. 17, 2014  The In ... topics that will be featured at the conference, which ... Center on December 3 and 4, 2014. Researchers, students, ... invited to hear the following: KEYNOTE ... San Diego Skaggs School of Pharmacy ...
(Date:9/17/2014)... Shimadzu Scientific Instruments introduces ... which offers a powerful separation method for ... provides a new level of knowledge and ... to scientists analyzing pharmaceutical impurities, proteins, lipids, ... Comprehensive 2D-LC combines two independent separation modes ...
(Date:9/17/2014)... 2014 A biodegradable polymer can ... as bacteria, fungi, and algae into smaller units ... inorganic compounds, carbon dioxide, and humus in a ... and improved costs, biodegradable polymers are proving to ... to conventional polymers. Primary factors that are responsible ...
(Date:9/17/2014)... , Sept. 17, 2014 BioClinica®, Inc., a ... Solutions, today announced three of its experts are speaking ... Clinical Data Management to be held September 28 to ... . The Company also announced the innovative Compass ... quality in clinical trials acquired earlier this year, is ...
Breaking Biology Technology:In Silico Drug Discovery Conference Announces Speakers and Topics 2In Silico Drug Discovery Conference Announces Speakers and Topics 3In Silico Drug Discovery Conference Announces Speakers and Topics 4In Silico Drug Discovery Conference Announces Speakers and Topics 5In Silico Drug Discovery Conference Announces Speakers and Topics 6In Silico Drug Discovery Conference Announces Speakers and Topics 7Shimadzu’s New Nexera-e Two Dimensional Comprehensive Liquid Chromatograph Empowers Laboratories to Separate Even the Most Complex Mixtures 2Growing Demand for Eco-Friendly Products Drives the Global Biodegradable Polymers Market, According to New Report by Global Industry Analysts, Inc. 2Growing Demand for Eco-Friendly Products Drives the Global Biodegradable Polymers Market, According to New Report by Global Industry Analysts, Inc. 3BioClinica to Present at 20th Annual SCDM Conference 2BioClinica to Present at 20th Annual SCDM Conference 3
... N.J., Sept. 22, 2011 Parent ... in the United States focused on finding a cure for ... awarded Tejvir S. Khurana, MD, PhD, Professor of Physiology at ... Duchenne Grant for $98,000. (Logo: http://photos.prnewswire.com/prnh/20100119/DC39975LOGO ...
... PrimeraDx today announced that Albert Luderer has been appointed ... CEO Matthew McManus commented:  "We are excited to have Al ... launched the ICE Plex System, which is the first ... qPCR, and Al brings many years of experience in the ...
... Neogen Corporation (NASDAQ: NEOG ) has developed ... considered by many to be the most potent, naturally-occurring carcinogen. ... wide range of commodities, including corn. Because it is a ... 100 countries have established regulatory limits for aflatoxin in commodities ...
Cached Biology Technology:Parent Project Muscular Dystrophy Awards End Duchenne Grant to University of Pennsylvania's Dr. Tejvir S. Khurana 2Parent Project Muscular Dystrophy Awards End Duchenne Grant to University of Pennsylvania's Dr. Tejvir S. Khurana 3PrimeraDx Appoints Albert A. Luderer to its Board of Directors 2Neogen Launches Fully Quantitative Lateral Flow Test for Aflatoxin 2
(Date:9/17/2014)... human retinoblastoma protein gene are a leading cause of ... to fruit fly eyes to unlock the secrets of ... featured on the cover of the current issue of ... University researchers provide the first detailed examination of a ... human cancer gene, said Irina Pushel, MSU undergraduate and ...
(Date:9/17/2014)... University] After decades of decline, grasses have returned ... the eye, the marsh in those places seems healthy ... key service of the marsh coastal protection ... the ecosystem function hasn,t come back," said ecologist Mark ... of the study in the journal Biological Conservation ...
(Date:9/17/2014)... social behavior by studying nonhuman mammals and primates, but ... their unusually large brains relative to their body size ... environment---not merely in a large population of cooperating creatures, ... setting of alliances and competitors. The same is true ... social carnivores, like hyenas and lions. , A new ...
Breaking Biology News(10 mins):Abnormal properties of cancer protein revealed in fly eyes 2Cape Cod saltmarsh recovery looks good, falls short 2Cape Cod saltmarsh recovery looks good, falls short 3Being social: Learning from the behavior of birds 2
... deadline for the European Congress on Osteoporosis & Osteoarthritis ... Thursday January 17, 2013. SUBMIT YOUR ABSTRACT ... yet registered?, Register now for Europe,s largest and most ... April 17-20, 2013. Featuring renowned speakers, ...
... With $14 million from the William & Nancy ... of Orange County, UC Irvine is helping lead the ... 88 children in the U.S. autism., The funding ... Southern California, which will provide unparalleled access to assessment, ...
... ornamental fish industry faces a global problem with antibiotic ... for fish diseases may not work when needed ... antibiotic-resistant bacteria. The risk to humans is probably ... compromised immune systems, researchers said, although transmission of disease ...
Cached Biology News:UCI research turns the corner on autism 2UCI research turns the corner on autism 3Ornamental fish industry faces increasing problems with antibiotic resistance 2Ornamental fish industry faces increasing problems with antibiotic resistance 3
Viral CMV UL146/vCXC1 Biotinylated Affinity Purified PAb...
D-biotin *50 mM aqueous solution* Secondary Detection Biotin–Avidin Detection Reagents Other...
Green Standard is fluorescein....
Human/Mouse/Rat LAR Affinity Purified PAb...
Biology Products: